WST

In the past six months, West Pharmaceutical Services reported strong second-quarter 2026 results, with organic sales increasing by 12.7% and adjusted diluted EPS rising by 28.8% to $2.37. Following these results, the company raised its full-year adjusted EPS target to $8.85-$9.05 and its revenue guidance to $3.3 billion-$3.4 billion. The company is scheduled to host its third-quarter 2026 conference call on October 8, 2026, and has participated in investor conferences and declared a quarterly dividend. Analyst sentiment has been positive, with upgrades from Morgan Stanley and UBS, and Citi raising its price target. Challenges included a temporary disruption to global operations due to a cyberattack in May, which was contained and fully recovered, and AbbVie's acquisition of a drug delivery system and manufacturing facility from West Pharmaceutical Services in July 2026. Insider selling of WST stock has also been reported. Despite these events, the stock price increased by 39.67% over the last 12 months and 6.15% in the past month as of October 10, 2026.